On Oct 31, major Wall Street analysts update their ratings for $Stryker Corp (SYK.US)$, with price targets ranging from $370 to $420.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and adjusts the target price from $325 to $420.
BofA Securities analyst Travis Steed maintains with a buy rating, and sets the target price at $400.
Citi analyst Joanne Wuensch maintains with a buy rating, and sets the target price at $411.
Barclays analyst Matt Miksic maintains with a buy rating, and adjusts the target price from $402 to $418.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $351 to $370.
Furthermore, according to the comprehensive report, the opinions of $Stryker Corp (SYK.US)$'s main analysts recently are as follows:
The company delivered a strong performance, underscored by an 11.5% organic growth and double-digit expansion across the majority of its significant segments, coupled with better-than-expected operating margins.
Stryker's Q3 outcomes surpassed expectations, demonstrating robust double-digit growth in both revenue and earnings, coupled with an increase in operating margins.
Stryker's recent financial performance exceeded expectations at the top line. Looking ahead to 2025, the company's growth is anticipated to be fueled by a series of new product introductions, the positive impact of mergers and acquisitions with an estimated seven deals poised to contribute to growth, and the ongoing increase in the utilization of Mako, particularly with two new indications. However, a neutral stance is being maintained until there is a clear indication of sales and EPS outperformance compared to the consensus.
Stryker demonstrated robust and varied performance in the third quarter, with revenues reaching $5.494B, surpassing expectations. While the company's implied organic growth rate of 7.5% - 8.0% is below its historical averages for a seasonally strong quarter, it still anticipates healthy procedural dynamics, positive pricing trends, and product development initiatives to maintain its superior growth trajectory.
The recent quarter showed a strong performance for Stryker, with global organic growth picking up pace to hit double digits, a notable positive shift in orthopedic pricing for the first time in ten years, and earnings per share expanding at or above the mid-teen range.
Here are the latest investment ratings and price targets for $Stryker Corp (SYK.US)$ from 15 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$史賽克 (SYK.US)$的評級，目標價介於370美元至420美元。
摩根大通分析師Robbie Marcus維持買入評級，並將目標價從325美元上調至420美元。
美銀證券分析師Travis Steed維持買入評級，目標價400美元。
花旗分析師Joanne Wuensch維持買入評級，目標價411美元。
巴克萊銀行分析師Matt Miksic維持買入評級，並將目標價從402美元上調至418美元。
瑞士銀行分析師Danielle Antalffy維持持有評級，並將目標價從351美元上調至370美元。
此外，綜合報道，$史賽克 (SYK.US)$近期主要分析師觀點如下：
公司表現強勁，有機增長率達到11.5％，在其重要領域的大部分業務都實現了兩位數增長，在運營利潤率超出預期的情況下實現了雙位數擴張。
斯特賴克（Stryker）第三季度的業績超出預期，展現出收入和盈利均實現強勁的雙位數增長，運營利潤率也有所提高。
斯特賴克最近的財務表現超出預期。展望2025年，公司的增長預計將受益於一系列新產品的推出，以及併購帶來積極影響，估計有七項交易將促進增長，並持續提高Mako的使用率，尤其是在兩個新適應症中。然而，對待觀望的立場將繼續保持，直至有明確的銷售額和每股收益超過共識的跡象。
斯特賴克第三季度表現強勁且多樣化，營收達到54.94億美元，超出預期。儘管公司暗含的有機增長率爲7.5％ - 8.0％低於歷史平均水平，但仍預計健康的程序動態、積極的定價趨勢和產品開發舉措將維持其出色的增長軌跡。
最近一個季度對斯特賴克來說表現強勁，全球有機增長加速至兩位數，整形外科產品價格首次在十年內顯著上漲，每股收益增長率達到或超過十五個百分點的區間。
以下爲今日15位分析師對$史賽克 (SYK.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
